Could gilteritinib keep AML in remission longer after transplant?
NCT ID NCT06734585
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times
Summary
This study looked at people with a type of leukemia (AML) that has a FLT3 gene change, which makes the cancer grow faster. After a stem cell transplant, some patients took the drug gilteritinib in earlier trials, while others received standard care. Researchers compared medical records to see if gilteritinib helped keep patients cancer-free longer. The study only collected existing data and did not provide any new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Gilteritinib (XOSPATA)
What this could lead to
If successful, this could confirm that gilteritinib helps keep FLT3-mutated AML patients cancer-free longer after a stem cell transplant, supporting its approval in more countries.
What could go wrong
This is an observational study using data from past trials and medical records, not a new treatment test. Results may not apply to all patients, and the comparison groups may differ in ways that affect outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AU61001
Melbourne, Australia
-
AU61002
Melbourne, Australia
-
BR55001
São Paulo, Brazil
-
BR55002
Porto Alegre, Brazil
-
BR55003
São Paulo, Brazil
-
BR55004
Fortaleza, Brazil
-
CN86001
Tianjin, China
-
CN86003
Shanghai, China
-
CN86004
Suzhou, China
-
HK852001
Hong Kong, Hong Kong
-
KR82001
Seoul, South Korea
-
KR82002
Seoul, South Korea
-
KR82003
Seoul, South Korea
-
KR82004
Busan, South Korea
-
KR82005
Gwangju, South Korea
-
TW88601
Taipei, Taiwan
-
TW88602
Tainan, Taiwan
-
TW88603
Taichung, Taiwan